Opinion|Videos|March 10, 2025
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety:
- JAK inhibitors
- Nemolizumab
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
5